Independent Meta-Analysis Shines Light on
Important Visualization Modality
CENTER
VALLEY, Pa., April 24,
2024 /PRNewswire/ -- Olympus, a global
medical technology company committed to making people's lives
healthier, safer, and more fulfilling, announced today data showing
that the use of Narrow Band Imaging (NBI) technology with patients
with non-muscle invasive bladder cancer (NMIBC) led to 37% less
likelihood of recurrence over 12-35 months.1
The data are drawn from the hazard ratio referenced in a
meta-analysis, "Narrow band imaging versus white light cystoscopy
alone for transurethral resection for non-muscle invasive bladder
cancer," published in 2022 in the Cochrane Database of Systematic
Reviews.1
"Without dyes, without any change to the patient's standard
cystoscopy, and with only a push of a button, urologists can better
visualize a lesion, and potentially contribute to reduced
recurrence of what is a notoriously recurrent cancer," said
Richard Reynolds, President, Olympus
Medical Systems Group. "As more urologists become aware of the
benefits of NBI technology, and as more studies are published, we
believe use of the modality will become the norm in an elevated
standard of care."
As reported by the American Cancer Society, bladder cancer has
one of the highest recurrence rates.2 Additionally,
"recurrence and progression to muscle-invasive bladder cancer
(MIBC) is highly variable, depending on tumor classification and
grade at diagnosis. For example, in patients diagnosed with
low-grade noninvasive urothelial carcinoma (Ta), recurrence rates
range from 30% to 60% at 5 years; however, the risk of progression
to MIBC is ≤5%. In contrast, patients with high-grade urothelial
carcinoma invading into the lamina propria (T1) have progression
rates of 30% to 70%." 2
Keeping a close eye on bladder cancer is critical because of
these recurrence rates, with patients typically undergoing
cystoscopy every 3-6 months for years after a
diagnosis.3
This recent recurrence data complements existing NBI technology
claims, indicating that, in comparison to white light, NBI
technology visualized NMIBC lesions in:
- 17% additional patients
- 24% additional tumors
- 28% additional Carcinoma In Situ (CIS ).4
NBI is not intended to replace histopathological sampling as a
means of diagnosis.
"Whether in the office or the OR setting, I find NBI technology
a necessary additional evaluation component in cystoscopy for
bladder cancer patients," said Michael B.
Williams, MD, MS, Associate Professor at Eastern Virginia Medical School. "Physicians should
know that training to incorporate NBI technology into their
practice is available and it does require some time to identify
lesions effectively. However, with additional analysis showing a
reduction in recurrence of NMIBC for patients whose physicians used
NBI technology, there are now more reasons to adopt use of this
visualization technique."
Recent start-up activity around NBI technology and bladder
cancer was recognized by Olympus in its selection of Vesica
AI, a promising medical startup company, as the winner of the
inaugural Olympus Asia Pacific Innovation Program (OAIP). Vesica AI
was chosen from a field of four finalists for its innovative
AI-based clinical visualization software that supports and enhances
the early detection of bladder cancer through the cystoscopy
procedure. Vesica AI is the result of a collaboration between the
University of Tsukuba Hospital in
Ibaraki prefecture, Japan, and the National Institute of Advanced
Industrial Science and Technology (AIST), a Japanese public agency
promoting scientific development. As the winning innovator, Vesica
AI will receive grant funding of $75,000 as well as an exclusive mentorship
program with key thought leaders from Olympus. The mentorship
program will connect Vesica AI with experts from Olympus in
meaningful ways that aim to support the future success of the
company.
Olympus provides information, images, video and more at the NBI
technology for urology product page. NBI technology will also be
available for demo at the Olympus booth at the American Urological
Association (AUA) conference, May 3-6,
2024, in San Antonio,
TX.
About Olympus
At Olympus, we are committed to our purpose of making people's
lives healthier, safer and more fulfilling. As a global medical
technology company, we partner with healthcare professionals
striving to provide best-in-class solutions and services for early
detection, diagnosis and minimally invasive treatment, aiming to
improve patient outcomes by elevating the standard of care in
targeted disease states. For more information,
visit medical.olympusamerica.com.
1 Lai LY, Tafuri SM, Ginier EC, Herrel LA, Dahm P,
Maisch P, Lane GI. Narrow band imaging versus white light
cystoscopy alone for transurethral resection of non-muscle invasive
bladder cancer. Cochrane Database Syst Rev. 2022 Apr 8;4(4):CD014887. doi:
10.1002/14651858.CD014887.pub2. PMID: 35393644; PMCID:
PMC8990285.
2
https://www.cancer.org/cancer/survivorship/long-term-health-concerns/recurrence/cancer-recurrence-rates.html
3
cancer.org/cancer/types/bladder-cancer/treating/by-stage.html
4 Li, K., Lin, T., Fan, X., Duan, Y., & Huang,
J. (2013). Diagnosis of narrow-band imaging in non-muscle-invasive
bladder cancer: A systematic review and meta-analysis.
International Journal of Urology, 20,
602-609. http://www.ncbi.nlm.nih.gov/pubmed/23113702
View original content to download
multimedia:https://www.prnewswire.com/news-releases/recurrence-data-for-narrow-band-imaging-nbi-technology-show-value-in-the-fight-against-non-muscle-invasive-bladder-cancer-302126421.html
SOURCE Olympus Corporation of the Americas